Frank Sinicrope, MD

@FASinicropeMD

Professor GI + Med Onc, researcher . Interests: , , therapeutics, . RT not endorsed. Views my own.

Rochester
Vrijeme pridruživanja: prosinac 2019.

Tweetovi

Blokirali ste korisnika/cu @FASinicropeMD

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FASinicropeMD

  1. proslijedio/la je Tweet

    Wuhan's first hospital built specially for receiving coronavirus patients completed on Sunday after 10 days of speedy construction. It will be managed by China's military medical system and start operation on Monday.

    Poništi
  2. proslijedio/la je Tweet
    30. sij

    Is nearly half of Early-Onset CRC(colorectal cancer) preventable?

    Poništi
  3. proslijedio/la je Tweet
    25. sij

    Wow!! Impressive response rate to Gem Cis in BRCA+ pancreatic cancer (ORR > 60%). New benchmark for this subset. Thanks to patient volunteers and research teams at and others

    Poništi
  4. proslijedio/la je Tweet
    26. sij

    A consensus statement on cancer associated fibroblasts (with the Who’s Who of CAF biology!) emanating from a meeting in 2019. so enjoy!

    Poništi
  5. proslijedio/la je Tweet
    24. sij

    Important message by and an approach I many others have adapted in BRCA+ -1st line platinum based regimen followed by parp maintenance is a top approach in this subset-parp haters don’t @ me

    Poništi
  6. proslijedio/la je Tweet
    23. stu 2019.

    Strong OS results from IMbrave150. A big step forward for cancer immunotherapy with atezo+bev and it’s impact on global health. Great for HCC patients. Wish we had this for my grandfather when he needed it years ago.

    Poništi
  7. 25. sij

    Equivalent efficacy of doublet and triplet reported in NEJM paper now confirmed.

    Poništi
  8. 25. sij

    Impressive data; should be new std of care for first line tx of MSI-H metastatic CRC.

    Poništi
  9. proslijedio/la je Tweet
    25. sij

    Dr. Susan Bullman of recaps her keynote lecture: How the Impacts Cancer, Immunity, and Response to Therapy

    Poništi
  10. proslijedio/la je Tweet
    23. sij

    This patient page on chemotherapy-induced peripheral () reviews risks, prevention, symptoms, and management of this common and challenging complication of treatment.

    Poništi
  11. proslijedio/la je Tweet
    23. sij

    Very nice summary of the standard of care in GEJ cancers in 2020 by Dr. Harry Yoon! And outstanding presentations in GE cancers session in the !

    Poništi
  12. proslijedio/la je Tweet
    22. sij

    Q&A: Christina Curtis on Computational and Systems Biology The article is freely available here:

    Poništi
  13. proslijedio/la je Tweet
    19. sij

    Thanks for inviting me to speak conference and highlight our efforts to characterize immune changes in the TME after standard therapy to include after atezolizumab+abraxane as part of TRIBUTE

    Poništi
  14. proslijedio/la je Tweet
    14. sij

    Great progress against cancer - here with a eloquent commentary.

    Poništi
  15. proslijedio/la je Tweet
    14. sij

    Very happy to have this manuscript completed, and the excellent partnership with . This one was almost three years in the making- and required evolution of the entire field to make possible. The importance of .

    Poništi
  16. proslijedio/la je Tweet
    3. lip 2019.

    , , Phase III randomized clinical trial in stage III colon cancer patients (n=1062) shows significant predictive value of Immunoscore.

    Poništi
  17. proslijedio/la je Tweet

    Come join us for our Education and Support Series on Thursday, January 16, 2020! Information and strategies to manage cancer-related fatigue will be shared. We hope to see you there!

    Poništi
  18. proslijedio/la je Tweet
    8. sij

    My patient (in the back somewhere) on Keynote-001 with now able to see the birth of 7 grandchildren due to the breakthrough (BTW he has 10 grandchildren) we are both

    Poništi
  19. proslijedio/la je Tweet
    7. sij

    The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff who have made this initiative possible. A few thoughts on what we have learned.

    Prikaži ovu nit
    Poništi
  20. proslijedio/la je Tweet

    Know an focusing on disparities? Encourage them to apply by Jan 21, 2020!

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·